This is a multicenter randomized controlled clinical trial designed to evaluate the clinical efficacy and cost-effectiveness of a digital health platform that integrates a symptom reporting and management software with a standardized telenursing program, allowing cancer patients to actively monitor, report, and self-manage chemotherapy-related adverse effects.
Adults aged 19 years or older
Diagnosed with early or advanced gastric, lung, breast, or colon cancer
Starting first-cycle chemotherapy with a new anticancer agent
Able to use a smartphone without difficulty
Individuals who have difficulty communicating due to cognitive impairment, visual impairment, hearing impairment, or other reasons
Individuals who cannot read, write, or understand Korean
Other individuals deemed inappropriate for participation by the investigators
Ulsan University Hospital
Lead sponsor
National Cancer Center, Korea
Collaborator
Kosin University Gospel Hospital
Collaborator
Gyeongsang National University Hospital
Collaborator
Gachon University Gil Medical Center
Collaborator